Volume 16, Number 8—August 2010
CME ACTIVITY - Research
Correlation of Pandemic (H1N1) 2009 Viral Load with Disease Severity and Prolonged Viral Shedding in Children
Table 3
Characteristic | No. (%) patients |
p value† | |
---|---|---|---|
Age <13 years, n = 31 | Age >13 years, n = 29 | ||
Sex, M/F |
14/17 |
15/14 |
0.611 |
Disease severity | |||
URI/bronchitis | 22 (71.0) | 22 (75.9) | 0.859‡ |
Pneumonia | 9 (29.0) | 5 (17.2) | |
Meningoencephalitis |
0 |
2 (6.9) |
|
Duration of fever after antiviral treatment, h | |||
<24 | 23 (74.2) | 26 (89.7) | 0.122§ |
24–48 | 5 (16.1) | 2 (6.9) | |
>48 |
3 (9.7) |
1 (3.4) |
|
Time to initiate antiviral treatment, h | |||
<48 | 25 (80.6) | 24 (82.8) | 0.833 |
>48 |
6 (19.4) |
5 (17.2) |
|
Viral load from the first throat swab, log10 copies/mL | |||
<4.35 | 16 (51.6) | 14 (48.3) | 0.796 |
>4.35 |
15 (48.4) |
15 (51.7) |
|
Coexisting condition | |||
Any 1 condition | 8 (25.8) | 6 (20.7) | 0.640 |
Asthma | 7 | 0 | |
Ventricular septal defect | 1 | 0 | |
Hypertension | 0 | 5 | |
Cerebrovascular disease | 0 | 1 | |
Congestive heart failure | 0 | 1 | |
Diabetes | 0 | 1 | |
Pregnancy | 0 | 1 |
*URI, upper respiratory tract infection.
†p values were calculated by χ2 test.
‡The URI/bronchitis group was compared with the combined group of pneumonia and meningoencephalitis.
§Fever lasting <24 h after antiviral treatment vs. fever lasting 24 h or longer after antiviral treatment.
Page created: March 30, 2011
Page updated: March 30, 2011
Page reviewed: March 30, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.